New data for Lantheus Medical Imaging's echocardiography contrast agent Definity and its BMS747158 fluorine-18-labeled PET agent for myocardial perfusion imaging will be presented in two poster presentations at the American College of Cardiology (ACC) meeting in Orlando, FL, next week.
Regarding Definity, new data on survival in an intensive care unit population undergoing transthoracic echocardiography with and without perflutren-containing ultrasound contrast agents will be presented.
The retrospective study includes more than 39,000 patients undergoing transthoracic echocardiography with and without contrast agents. The majority of the perflutren cases used Definity.
Additionally, phase I data regarding the human safety, dosimetry, biodistribution, and myocardial perfusion imaging characteristics under rest and stress conditions of the North Billerica, MA-based company's BMS747158 PET agent will be presented.
In preclinical studies, the agent has demonstrated high, rapid, and sustained cardiac uptake, which is proportional to myocardial perfusion over a wide range of blood-flow rates. The agent also has shown high target to nontarget uptake ratios, perfusion defect recognition, and high image quality in multiple species.
Related Reading
Lantheus taps new VP, March 24, 2009
Study: Echo with Definity contrast aids in cardiac diagnosis, February 24, 2009
SPECT MPI works for CAD, Lantheus says, January 27, 2009
Lantheus touts positive Definity results, December 16, 2008
Lantheus scores Premier contract, October 24, 2008
Copyright © 2009 AuntMinnie.com
